{"id":"NCT01281839","sponsor":"Janssen R&D Ireland","briefTitle":"An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon Î±-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects Who Relapsed After Previous Interferon-based Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2011-01-24","resultsPosted":"2014-04-23","lastUpdate":"2014-04-23"},"enrollment":394,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Peginterferon alpha-2a (PegIFN alpha-2a)","otherNames":["Pegasys"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["Copegus"]}],"arms":[{"label":"TMC435","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the effectiveness and safety of TMC435 compared with placebo in patients who are infected with genotype 1 hepatitis C virus who relapsed after previous interferon-based therapy. Patients will also receive peginterferon alfa-2a and ribavirin as part of their treatment.","primaryOutcome":{"measure":"The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)","timeFrame":"Week 36 or Week 60","effectByArm":[{"arm":"TMC435 150mg 12Wks PR24/48","deltaMin":79.2,"sd":null},{"arm":"PBO 12Wks PR48","deltaMin":36.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":68,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","New Zealand","Poland","Puerto Rico","Russia","Spain","United Kingdom"]},"refs":{"pmids":["25445400","24602923"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":260},"commonTop":["Fatigue","Headache","Pruritus","Influenza like illness","Pyrexia"]}}